title: [Prognostic factors in breast cancer].
abstract: Among the various factors reported as having significant prognostic value in primary breast cancers, the author discusses the value of well established "classical" prognostic factors used routinely and "new" prognostic factors developed over recent years as a result of progress in cell and molecular biology. The presence of axillary lymph node metastases remains the most important prognostic factor of recurrence, justifying post-surgical adjuvant therapy. However, in patients with negative axillary nodes (N-), the size of the tumour, Scarff-Bloom-Richardson (SBR and MSBR) histological grade, certain particular histological types (carcinoma in situ and tubular, colloid or pure papillary cancer) and hormone receptors (ER and PR) appear to be well established prognostic factors allowing the identification, within this group of N- patients who generally have a good prognosis, those patients with a low risk of recurrence and therefore not requiring adjuvant therapy. In contrast, the proliferative activity (ploidy and S phase, Thymidine Labeling Index, antibody Ki67), cathepsin D, thymidine kinase, EGF receptors, several genes including oncogene HER-2/neu, are recently developed prognostic factors whose significance needs to be confirmed by further studies.
authors.affiliation: Laboratoire Henry Bonneau, Marseille.
authors.forename: P
authors.initials: P
authors.lastname: Meynard
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis* / Q000473:pathology; D002402:Cathepsin D / Q000032:analysis; D066246:ErbB Receptors / Q000032:analysis; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011003:Ploidies; D011379:Prognosis; D011959:Receptors, Estradiol / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D015996:Survival Rate
chemical_list: D011959:Receptors, Estradiol; D011980:Receptors, Progesterone; D066246:ErbB Receptors; D002402:Cathepsin D
vernacular_title: Les facteurs de pronostic des cancers du sein.